GlassScriptPhysician profile
Deborah S Demuro
NPI 1902005630
$939.80
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $851 · 2022: $89.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $504.08 | 2021 | |
| Endo Pharmaceuticals INC. | $142.61 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $105.22 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $38.43 | 2021 | |
| Abbvie INC. | $34.99 | 2021 | |
| Myovant Sciences INC. | $27.65 | 2021 | |
| Urovant Sciences INC | $25.13 | 2021-2022 | |
| Pfizer INC. | $16.66 | 2022 | |
| Merck Sharp & Dohme LLC | $16.53 | 2021 | |
| Janssen Biotech, INC. | $15.38 | 2021 | |
| Photocure INC | $13.12 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Demuro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.